News
EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Lomiko Metals engages DRA Americas to lead the pre-feasibility level engineering studies for the La Loutre Natural Flake Graphite Project in Quebec, Canada
Lomiko Metals Inc. (TSX.V: LMR) (“Lomiko Metals” or the “Company”) is pleased to announce it is continuing with the pre-feasibility level engineering studies for its wholly owned La Loutre natural
GenSight Biologics Annual General Meeting on May 13, 2025
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Fuller, Smith & Turner PLC: Transaction in own shares
Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc
Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
EQS-News: Your Family Entertainment AG: Successful placement of convertible bond 2025/2028
Rand Capital Announces First Quarter 2025 Financial Results Conference Call and Webcast
Rand Capital Corporation (Nasdaq: RAND) (“Rand” or the “Company”), a business development company providing alternative financing for lower middle market companies, announced that it plans to
Fuller, Smith & Turner PLC: Transaction in own shares
R.E.A. Holdings plc: Conditional agreement for the sale of CDM
Lomiko Metals Announces the closing of the first tranche of the Private Placement
Lomiko Metals Inc. (TSX.V: LMR) (“Lomiko” or the “Company”) is pleased to announce it will apply to the TSX Venture Exchange (the “Exchange”) to close the first tranche of the non-brokered private
Form 8.3 - The Vanguard Group, Inc.: Urban Logistics REIT plc
Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc
Form 8.3 - The Vanguard Group, Inc.: PRS REIT plc, The
Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Granite REIT Declares Distribution for April 2025
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2833 per unit for the month of April
Fuller, Smith & Turner PLC: Transaction in own shares
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product